Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC : vimarsana.com

Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.

Related Keywords

Spain , Massachusetts , United States , Virginia , Boston , Charlottesville , Italy , Milan , Lombardia , University Of Virginia , Barcelona , Comunidad Autonoma De Cataluna , Maria Rosario Garcia Campelo , Ryand Gentzler , Enriqueta Felip , Merck Serono , Antonio Passaro , Daiichi Sankyo , Zofia Piotrowska , Eli Lilly , Society For Immunotherapy Of Cancer , Jazz Pharmaceuticals , University Hospitala Coru , European Institute Of Oncology , Glaxosmithkline , Janssen Pharmaceuticals , Novartis , Bristol Myers Squibb , Investigational Drug Steering Committee , Boehringer Ingelheim , Hebron University Hospital , Pfizer , European Lung Cancer Congress , Hoosier Cancer Research Network , Cancer Center , Drug Administration , Genentech , Amgen , Big Ten Research Consortium , Scientific Review Committee , Alliance Foundation , Division Of Thoracic Oncology , Astrazeneca , Thoracic Clinical Trial Working Group , Thoracic Oncology , European Institute , Medscape Medical , University Hospital , Massachusetts General Cancer Center , Medical Trends , Medscape Medical News , Merck Sharp , Turning Point Therapeutics , Jounce Therapeutics , Clinical Care Options , Targeted Oncology , International Association , Lung Cancer , Blueprint Medicines , Review Committee , Clinical Oncology , Drug Steering ,